Abstract
The more profound understanding of the genetics and molecular pathways driving human tumorigensis is paralleled by an ongoing interest to translate this knowledge into development of cancer biomarkers, termed molecular tumor markers. The molecular changes observed in tumors frequently constitute early events which are detectable as signatures of malignancy in body fluids and their occurrence may preceede clinical cancer diagnosis. Thus, beyond applicability on tissue samples, molecular markers for tumor signatures should allow noninvasive or minimally invasive diagnosis in blood and / or other body fluid samples. However, to qualify as a clinically useful molecular tumor marker for initial diagnosis and detection of recurrent disease, a molecular tumor marker must have better test characteristics (sensitivity, specifity) than currently applied tumor markers. A molecular tumor marker should also be suitable for screening purposes by defining the subset of individuals for which definite cancer diagnosis by more invasive and/or expensive additional investigations is indicated. In addition, there is a demand for molecular tumor markers to be used as reliable surrogate endpoints in cancer prevention trials. Recommondation for the use of individual molecular tumor markers within evidence-based medicine criteria should ideally be derived from their overall efficacy to reduce tumor-specific mortality. This review focuses on DNA based, RNA based and proteomics based molecular methods of noninvasive cancer detection in bodily fluids and asseses the value of these methods for the current and future clinical management of cancer patients.
Keywords: noninvasive, molecular, proteomic, translational medicine, circulating nucleic acids, circulating tumor cells
Current Medicinal Chemistry
Title: Noninvasive Molecular Detection of Cancer - the Bench and the Bedside
Volume: 10 Issue: 8
Author(s): Carsten Goessl
Affiliation:
Keywords: noninvasive, molecular, proteomic, translational medicine, circulating nucleic acids, circulating tumor cells
Abstract: The more profound understanding of the genetics and molecular pathways driving human tumorigensis is paralleled by an ongoing interest to translate this knowledge into development of cancer biomarkers, termed molecular tumor markers. The molecular changes observed in tumors frequently constitute early events which are detectable as signatures of malignancy in body fluids and their occurrence may preceede clinical cancer diagnosis. Thus, beyond applicability on tissue samples, molecular markers for tumor signatures should allow noninvasive or minimally invasive diagnosis in blood and / or other body fluid samples. However, to qualify as a clinically useful molecular tumor marker for initial diagnosis and detection of recurrent disease, a molecular tumor marker must have better test characteristics (sensitivity, specifity) than currently applied tumor markers. A molecular tumor marker should also be suitable for screening purposes by defining the subset of individuals for which definite cancer diagnosis by more invasive and/or expensive additional investigations is indicated. In addition, there is a demand for molecular tumor markers to be used as reliable surrogate endpoints in cancer prevention trials. Recommondation for the use of individual molecular tumor markers within evidence-based medicine criteria should ideally be derived from their overall efficacy to reduce tumor-specific mortality. This review focuses on DNA based, RNA based and proteomics based molecular methods of noninvasive cancer detection in bodily fluids and asseses the value of these methods for the current and future clinical management of cancer patients.
Export Options
About this article
Cite this article as:
Goessl Carsten, Noninvasive Molecular Detection of Cancer - the Bench and the Bedside, Current Medicinal Chemistry 2003; 10 (8) . https://dx.doi.org/10.2174/0929867033457872
DOI https://dx.doi.org/10.2174/0929867033457872 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inhibition of RNA Virus Infections with Peptide-Conjugated Morpholino Oligomers
Current Pharmaceutical Design Benzodiazepine Metabolism: An Analytical Perspective
Current Drug Metabolism Synthesis and Evaluation of A Water-Soluble Epothilone B Prodrug with Remarkably Decreased Toxicity
Letters in Organic Chemistry Editorial [Hot Topic: Plants as Sources of Therapeutic Proteins (Executive Editor: Schuyler S. Korban)]
Current Pharmaceutical Design From Antimicrobial to Anticancer Peptides: The Transformation of Peptides
Recent Patents on Anti-Cancer Drug Discovery 1,2,4-Triazine Analogs as Novel Class of Therapeutic Agents
Mini-Reviews in Medicinal Chemistry Rat Resources in Biomedical Research
Current Pharmaceutical Biotechnology Development of Novel Combined Time and pH-Dependent based Drug Delivery Systems for Targeting 5-Fluorouracil to the Colon
Current Drug Delivery Aging, Mitochondria and Male Reproductive Function
Current Aging Science New Cell Therapy Using Bone Marrow-Derived Stem Cells/Endothelial Progenitor Cells to Accelerate Neovascularization in Healing of Experimental Ulcerative Colitis
Current Pharmaceutical Design Roles of Laminin-332 and α6β4 Integrin in Tumor Progression
Mini-Reviews in Medicinal Chemistry Evaluation of Local Injection of Bevacizumab against Triple-Negative Breast Cancer Xenograft Tumors
Current Pharmaceutical Design Physiopathological Premises to Nuclear Medicine Imaging of Pancreatic Neuroendocrine Tumours
Current Radiopharmaceuticals Antisense Oligonucleotide Drug Design
Current Pharmaceutical Design Cellular Toxicity and Apoptosis Studies in Osteocarcinoma Cells, a Comparison of 177Lu-EDTMP and Lu-EDTMP
Current Radiopharmaceuticals Editorial (Thematic Issue: GPCR-Targeted Drug Development)
Current Drug Targets Synthetic Routes and Biological Activities of Benzofuran and its Derivatives: A Review
Letters in Organic Chemistry Dual Inhibitors of Src and Abl Tyrosine Kinases
Drug Design Reviews - Online (Discontinued) Geldanamycin, Radicicol, and Chimeric Inhibitors of the Hsp90 Nterminal ATP Binding Site
Current Topics in Medicinal Chemistry Bioactive Polyphenols from Grapes and Wine Emphasized with Resveratrol
Current Pharmaceutical Design